CME Group Inc. (NASDAQ:CME) reported its Q4 results, with EPS coming in at $1.66, slightly above the consensus estimate of $1.63. Revenue was $1.1 billion, compared to the consensus estimate of $1.17 billion. Analysts at Deutsche Bank provided their views on the company following the results. While viewing the quarterly results as being mixed, with weaker than expected revenue more than offset by solid cost control, the analysts see the company's position into 2022 as having improved, noting the following key drivers:

(1) Better cost control, with 2022 adjusted operating expenses likely staying flattish compared to the previous year.

(2) A favorable volume backdrop within interest rates and equity indices, as well as in energy & commodities.

(3) Continued product innovation that can enhance the longer-term revenue growth profile at least modestly.

Thus, the brokerage now sees a solid 2022 operating leverage dynamic with potential for high single-digit revenue growth against a flattish expense base, that could drive double-digit EPS growth, at least in 2022. The analysts raised their price target on the company’s shares to $260 from $235, while maintaining their hold rating.